Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics) is engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue. As of April 30, 2011, the Company is developing Oxycyte, a systemic perfluorcarbon (PFC), product. It has developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. In addition, Oxygen Biotherapeutics has also have under development Vitavent, an oxygen exchange fluid for facilitating the treatment of lung conditions, and it has out-licensed its rights to a biosensor implant product that uses an enzyme process for measuring the glucose level in subcutaneous fluid.